The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
The RaPID Platform for the Discovery of Pseudo-Natural Macrocyclic Peptides
Open accessAbstract
ConspectusAlthough macrocyclic peptides bearing exotic building blocks have proven their utility as pharmaceuticals, the sources of macrocyclic peptide drugs have been largely limited to mimetics of native peptides or natural product peptides. However, the recent emergence of technologies for discovering de novo bioactive peptides has led to their reconceptualization as a promising therapeutic modality. For the construction and screening of libraries of such macrocyclic peptides, our group has devised a platform to conduct affinity-based selection of massive libraries (>1012 unique sequences) of in vitro expressed macrocyclic peptides, which is referred to as the random nonstandard peptides integrated discovery (RaPID) system. The RaPID system integrates genetic code reprogramming using the FIT (flexible in vitro translation) system, which is largely facilitated by flexizymes (flexible tRNA-aminoacylating ribozymes), with mRNA display technology.We have demonstrated that the RaPID system enables rapid discovery of various de novo pseudo-natural peptide ligands for protein targets of interest. Many examples discussed in this Account prove that thioether-closed macrocyclic peptides (teMPs) obtained by the RaPID system generally exhibit remarkably high affinity and specificity, thereby potently inhibiting or activating a specific function(s) of the target. Moreover, such teMPs are used for a wide range of biochemical applications, for example, as crystallization chaperones for intractable transmembrane proteins and for in vivo recognition of specific cell types. Furthermore, recent studies demonstrate that some teMPs exhibit pharmacological activities in animal models and that even intracellular proteins can be inhibited by teMPs, illustrating the potential of this class of peptides as drug leads.Besides the ring-closing thioether linkage in the teMPs, genetic code reprogramming by the FIT system allows for incorporation of a variety of other exotic building blocks. For instance, diverse nonproteinogenic amino acids, hydroxy acids (ester linkage), amino carbothioic acid (thioamide linkage), and abiotic foldamer units have been successfully incorporated into ribosomally synthesized peptides. Despite such enormous successes in the conventional FIT system, multiple or consecutive incorporation of highly exotic amino acids, such as d- and β-amino acids, is yet challenging, and particularly the synthesis of peptides bearing non-carbonyl backbone structures remains a demanding task. To upgrade the RaPID system to the next generation, we have engaged in intensive manipulation of the FIT system to expand the structural diversity of peptides accessible by our in vitro biosynthesis strategy. Semilogical engineering of tRNA body sequences led to a new suppressor tRNA (tRNAPro1E2) capable of effectively recruiting translation factors, particularly EF-Tu and EF-P. The use of tRNAPro1E2 in the FIT system allows for not only single but also consecutive and multiple elongation of exotic amino acids, such as d-, β-, and γ-amino acids as well as aminobenzoic acids. Moreover, the integration of the FIT system with various chemical or enzymatic posttranslational modifications enables us to expand the range of accessible backbone structures to non-carbonyl moieties prominent in natural products and peptidomimetics. In such systems, FIT-expressed peptides undergo multistep backbone conversions in a one-pot manner to yield designer peptides composed of modified backbones such as azolines, azoles, and ring-closing pyridines. Our current research endeavors focus on applying such in vitro biosynthesis systems for the discovery of bioactive de novo pseudo-natural products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnison, P. G., Bibb, M. J., Bierbaum, G., Bowers, A. A., Bugni, T. S., Bulaj, G., Camarero, J. A., Campopiano, D. J., Challis, G. L., Clardy, J., et al. (2013) · Nat. Prod. Rep. · doi:10.1039/c2np20085f · Cited by 2,076
The exploration of macrocycles for drug discovery — an underexploited structural class
Driggers, E. M., Hale, S. P., Lee, J., & Terrett, N. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2590 · Cited by 1,370
RNA-peptide fusions for the in vitro selection of peptides and proteins
Roberts, R. W., & Szostak, J. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12297 · Cited by 1,105
New developments in RiPP discovery, enzymology and engineering
Montalbán-López, M., Scott, T. A., Ramesh, S., Rahman, I. R., van Heel, A. J., Viel, J. H., Bandarian, V., Dittmann, E., Genilloud, O., Goto, Y., et al. (2021) · Natural Product Reports · doi:10.1039/d0np00027b · Cited by 787
Self-citationSchmidt, E. W., Nelson, J. T., Rasko, D. A., Sudek, S., Eisen, J. A., Haygood, M. G., & Ravel, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501424102 · Cited by 567
Macrocycles: lessons from the distant past, recent developments, and future directions
Yudin, A. K. (2015) · Chemical Science · doi:10.1039/c4sc03089c · Cited by 493
EF-P Is Essential for Rapid Synthesis of Proteins Containing Consecutive Proline Residues
Doerfel, L. K., Wohlgemuth, I., Kothe, C., Peske, F., Urlaub, H., & Rodnina, M. V. (2013) · Science · doi:10.1126/science.1229017 · Cited by 489
Flexizymes for genetic code reprogramming
Goto, Y., Katoh, T., & Suga, H. (2011) · Nature Protocols · doi:10.1038/nprot.2011.331 · Cited by 472
Self-citationA highly flexible tRNA acylation method for non-natural polypeptide synthesis
Murakami, H., Ohta, A., Ashigai, H., & Suga, H. (2006) · Nature Methods · doi:10.1038/nmeth877 · Cited by 468
Self-citationTranslation Elongation Factor EF-P Alleviates Ribosome Stalling at Polyproline Stretches
Ude, S., Lassak, J., Starosta, A. L., Kraxenberger, T., Wilson, D. N., & Jung, K. (2013) · Science · doi:10.1126/science.1228985 · Cited by 463
Cited by
Cyclic Peptides for Drug Development
Ji, X., Nielsen, A. L., & Heinis, C. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202308251 · Cited by 411
Design of Cyclic Peptides Targeting Protein–Protein Interactions Using AlphaFold
(2023) · doi:10.3390/ijms241713257 · Cited by 51
Facilitating the structural characterisation of non-canonical amino acids in biomolecular NMR
Kuschert, S., Stroet, M., Chin, Y. K.-Y., Conibear, A. C., Jia, X., Lee, T., Bartling, C. R. O., Strømgaard, K., Güntert, P., Rosengren, K. J., et al. (2023) · Magnetic Resonance · doi:10.5194/mr-4-57-2023 · Cited by 9
De novo design of a fusion protein tool for GPCR research
(2025) · doi:10.1073/pnas.2422360122 · Cited by 8
Development and structure-guided characterization of a novel ACE2-binding macrocyclic peptide
Benoit, R. M., Wang, J., Beyer, D., Abbas, A., Rodrigues, M. J., Wieser, M. M., Deupi, X., Müller, C., Suga, H., & Bode, J. W. (2026) · Journal of Structural Biology: X · doi:10.1016/j.yjsbx.2026.100145
“With the ultimate aim to develop novel ACE2 radiotracers, we utilized the “ Random non-standard Peptides Integrated Discovery ” (RaPID) platform (Goto and Suga, 2021) to generate a macrocyclic peptide, WJL-63, that specifically binds to ACE2.”
Self-citation
Metadata
- Authors
- Goto, Y., & Suga, H.
- Venue
- Accounts of Chemical Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-09-10
- Volume
- 54
- Issue
- 18
- Pages
- 3604-3617
- ISSN
- 0001-4842 (ISSN-L)
- 1520-4898
- OpenAlex
- W3196622003
- Cited by
- 262
- References
- 76
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The RaPID Platform for the Discovery of Pseudo-Natural Macrocyclic Peptides. https://app.cochat.ai/papers/10.1021/acs.accounts.1c00391
- The paper
- Goto, Y., & Suga, H. (2021). The RaPID Platform for the Discovery of Pseudo-Natural Macrocyclic Peptides. Accounts of Chemical Research. https://doi.org/10.1021/acs.accounts.1c00391
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.